Pharma: Clinic Roundup
Tuesday, May 22, 2012
Janssen Research & Development, of Raritan, N.J., a unit of Johnson & Johnson, reported findings showing that subcutaneous induction regimens of anti-TNF-alpha therapy Simponi (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.